STOCK TITAN
  1. Home
  2. News
  3. GILD

Gilead Sciences, Inc. - GILD STOCK NEWS

Welcome to our dedicated news page for Gilead Sciences (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gilead Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gilead Sciences's position in the market.

News
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
Rhea-AI Summary
Kite, a Gilead Company (Nasdaq: GILD), announced the three-year follow-up analysis of ZUMA-12, a Phase 2 study of Yescarta® (axicabtagene ciloleucel) as first-line treatment after chemoimmunotherapy in high-risk, large b-cell lymphoma (LBCL) patients. The results demonstrated an 86% complete response rate and an 81% three-year estimate for overall survival, indicating the potential of Yescarta as a first-line treatment option for high-risk LBCL patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
none
-
News
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) has been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World) for the third consecutive year. The company was also included on the Dow Jones Sustainability North America Index (DJSI North America). These rankings are based on an in-depth analysis of Gilead’s sustainability performance, highlighting the company’s longstanding sustainable business practices and transparency on environmental, social, and governance (ESG) issues. Gilead’s ESG strategy aims to position the company as an employer of choice that delivers shareholder value in a sustainable, responsible manner. The company's focus on scientific innovation and sustainable business practices is centered around the needs of patients, employees, and communities around the world.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
none
-
News
Gilead's Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
Rhea-AI Summary
Gilead Sciences, Inc. (NASDAQ:GILD) announced new data supporting the use of Trodelvy in metastatic triple-negative breast cancer and pre-treated HR+/HER2- metastatic breast cancer patients at the SABCS 2023. The data will be presented in eight abstracts, reinforcing Trodelvy's use in these difficult-to-treat breast cancers. Trodelvy is the first approved Trop-2-directed ADC to significantly improve survival in both mTNBC and pre-treated HR+/HER2- metastatic breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none
News
Gilead Employees Stitch Together To Create a Special Panel of the AIDS Quilt
Rhea-AI Summary
Gilead Sciences (GILD) employees collaborate to create a special panel of the AIDS Memorial Quilt, dedicated to honoring loved ones lost to HIV. The project involved over 100 volunteers and is a tribute to those impacted by HIV, with the panel displayed at various locations including the National AIDS Memorial in San Francisco and Mexico City.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
none
-
News
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) to present new data at San Antonio Breast Cancer Symposium 2023 supporting the use of Trodelvy in certain metastatic triple-negative breast cancer and pre-treated HR+/HER2- metastatic breast cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
-
News
Gilead's Ambition: To Help End the HIV Epidemic
Rhea-AI Summary
Gilead Sciences, Inc. (GILD) aims to end the HIV epidemic globally through community partnerships and innovative medicines. The company collaborates with organizations like GNP+, UNAIDS, and PEPFAR to expand access to care in low- and middle-income countries. Gilead operates in over 35 countries and is headquartered in Foster City, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
News
Gilead Sciences: Breaking Barriers to Breast Cancer Care in Rural Areas
Rhea-AI Summary
Gilead Sciences (GILD) Director of Community Health Access and Relations, Claudia Hardy, is working to bring cancer resources and preventive care to underserved communities in Alabama. As the director of Community Health Access and Relations for the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Claudia's personal experience growing up in a medically underserved area and a food desert gives her a unique understanding of the barriers to cancer care in rural areas. She aims to address the lack of transportation, medical lingo comprehension, and access to comprehensive treatment in these communities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
none
-
News
Kite and Arcellx Announce Expansion in Strategic Partnership
Rhea-AI Summary
Gilead (GILD) & Arcellx (ACLX) expand collaboration for CART-ddBCMA & ARC-SparX program ACLX-001. Kite exercises option to negotiate license for ARC-SparX program ACLX-001 in multiple myeloma. Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment. The collaboration aims to bring potentially best-in-class cell therapy to patients, expanding opportunities in lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
partnership
-
News
ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
Rhea-AI Summary
Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), have expanded their collaboration, with Kite investing $200M at $61.68 per share and an $85 million upfront cash payment. Kite exercised its option to Arcellx's ARC-SparX program ACLX-001 in multiple myeloma and expanded the collaboration to include lymphomas. This investment is anticipated to extend Arcellx's cash runway into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
partnership
News
Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq:GILD) - Gilead Recognized as Top Funder of Health Equity Programs for BIPOC and LGBTQ+ Communities
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
Stock GILD logo
Gilead Sciences, Inc.

Nasdaq:GILD

GILD Rankings

#135 Ranked by Market Cap
#2131 Ranked by Stock Gains
#712 Ranked by Dividends

GILD Stock Data

84.88B
1.24B
0.09%
88.37%
1.81%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Foster City

About GILD

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.